Search

Author/Creator Walsh, Meghara

1. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies. Issue 15 (19th May 2016)

Authors:
McKay, Rana R.; De Velasco, Guillermo; Werner, Lillian; Bellmunt, Joaquim; Harshman, Lauren; Sweeney, Christopher; Rosenberg, Jonathan E.; Hirsch, Michelle; Signoretti, Sabina; Van Allen, Eliezer M.; Walsh, Meghara; Vaishampayan, Ulka; McDermott, David F.; Choueiri, Toni K.
Journal:
Cancer
Issue:
Volume 122:Issue 15(2016)
Page Start:
2389
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti‐Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma. (6th September 2018)

Authors:
Choueiri, Toni K.; Michaelson, M. Dror; Posadas, Edwin M.; Sonpavde, Guru P.; McDermott, David F.; Nixon, Andrew B.; Liu, Yingmiao; Yuan, Zhenhua; Seon, Ben K.; Walsh, Meghara; Jivani, Manoj A.; Adams, Bonne J.; Theuer, Charles P.
Journal:
Oncologist
Issue:
Volume 24:Number 2(2019)
Page Start:
202
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. (May 2018)

Authors:
Choueiri, Toni K.; Hessel, Colin; Halabi, Susan; Sanford, Ben; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Olencki, Thomas; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; George, Daniel; Morris, Michael J.
Journal:
European journal of cancer
Issue:
Volume 94(2018)
Page Start:
115
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. (9th August 2019)

Authors:
George, Daniel J.; Hessel, Colin; Halabi, Susan; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; Morris, Michael J.; Choueiri, Toni K.
Journal:
Oncologist
Issue:
Volume 24:Number 11(2019)
Page Start:
1497
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Clinical Results and Biomarker Analyses of Axitinib and TRC105 versus Axitinib Alone in Patients with Advanced or Metastatic Renal Cell Carcinoma (TRAXAR). (29th April 2021)

Authors:
Choueiri, Toni K.; Zakharia, Yousef; Pal, Sumanta; Kocsis, Judit; Pachynski, Russell; Poprach, Alexandr; Nixon, Andrew B.; Liu, Yingmiao; Starr, Mark; Lyu, Jing; Owzar, Kouros; deShazo, Mollie; Lara, Primo; Geczi, Lajos; Ho, Thai H.; Walsh, Meghara; Adams, Bonne; Robertson, Liz; Darif, Mohamed; T...
Journal:
Oncologist
Issue:
Volume 26:Number 7(2021)
Page Start:
560
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Corrigendum to 'Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update' [Eur J Cancer 94 (May 2018) 115–125]. (November 2018)

Authors:
Choueiri, Toni K.; Hessel, Colin; Halabi, Susan; Sanford, Ben; Michaelson, M. Dror; Hahn, Olwen; Walsh, Meghara; Olencki, Thomas; Picus, Joel; Small, Eric J.; Dakhil, Shaker; Feldman, Darren R.; Mangeshkar, Milan; Scheffold, Christian; George, Daniel; Morris, Michael J.
Journal:
European journal of cancer
Issue:
Volume 103(2018)
Page Start:
287
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗